{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:38:46Z","timestamp":1792543126970,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272886"],"award-info":[{"award-number":["82272886"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200484"],"award-info":[{"award-number":["82200484"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cancer cell dormancy presents a major obstacle to curative therapy, particularly in metastatic prostate cancer. Although the initial efficacy of hormonal therapy is satisfying, tumors will inevitably develop resistance. Dormant tumor cells may act as the initial source for the tumor recurrence, but the underlying mechanism remains largely unknown. Here we report that the glutamine synthesis pathway is required for cellular dormancy under androgen-deprived conditions. The key enzyme, glutamine synthetase (encoded by glutamate-ammonia ligase, GLUL), is upregulated during hormonal therapy, which leads to overabundant glutamine as a nutrient and an energy storage for tumor recurrence. The negative modulation of androgen receptor (AR) on GLUL enables activation of glutamine anabolism when AR is inhibited. Pharmacologically inhibiting GS\u2019s activity along with hormonal therapy results in cell apoptosis instead of dormancy, which significantly delays the progression of tumors into advanced PCa. In summary, we provide a novel perspective of how hormonal therapy eventually fails and highlight a combination treatment strategy to overcome therapeutic resistance of current hormonal therapy.<\/jats:p>","DOI":"10.1038\/s41420-026-03282-w","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:27:23Z","timestamp":1787801243000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Glutamine synthesis pathway promotes the survival and recurrence of dormant tumor cells in prostate cancer"],"prefix":"10.1038","volume":"12","author":[{"given":"Bing","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8137-4456","authenticated-orcid":false,"given":"Qingwei","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hekang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9205-1603","authenticated-orcid":false,"given":"Hailiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2465-241X","authenticated-orcid":false,"given":"Lingfan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"3282_CR1","first-page":"485","volume":"75","author":"TB Kratzer","year":"2025","unstructured":"Kratzer TB, Mazzitelli N, Star J, Dahut WL, Jemal A, Siegel RL. Prostate cancer statistics, 2025. CA Cancer J Clin. 2025;75:485\u201397.","journal-title":"CA Cancer J Clin"},{"key":"3282_CR2","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/jama.2025.0228","volume":"333","author":"R Raychaudhuri","year":"2025","unstructured":"Raychaudhuri R, Lin DW, Montgomery RB. Prostate cancer: a review. JAMA. 2025;333:1433\u201346.","journal-title":"JAMA"},{"key":"3282_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.eururo.2025.05.006","volume":"88","author":"E Mazzone","year":"2025","unstructured":"Mazzone E, Thomson A, Chen DC, Cannoletta D, Quarta L, Pellegrino A, et al. The role of prostate-specific membrane antigen positron emission tomography for assessment of local recurrence and distant metastases in patients with biochemical recurrence of prostate cancer after definitive treatment: a systematic review and meta-analysis. Eur Urol. 2025;88:129\u201341.","journal-title":"Eur Urol"},{"key":"3282_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.218097","volume":"635","author":"Y Wang","year":"2025","unstructured":"Wang Y, Liu L, Zhang X, Liang T, Bai X. Cancer dormancy and metabolism: from molecular insights to translational opportunities. Cancer Lett. 2025;635:218097.","journal-title":"Cancer Lett"},{"key":"3282_CR5","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/d41586-025-04149-3","volume":"649","author":"A Heidt","year":"2026","unstructured":"Heidt A. Why cancer can come back years later\u2014and how to stop it. Nature. 2026;649:282\u20134.","journal-title":"Nature"},{"key":"3282_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02250-9","volume":"24","author":"S Yang","year":"2025","unstructured":"Yang S, Seo J, Choi J, Kim SH, Kuk Y, Park KC, et al. Towards understanding cancer dormancy over strategic hitching up mechanisms to technologies. Mol Cancer. 2025;24:47.","journal-title":"Mol Cancer"},{"key":"3282_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02499-0","volume":"24","author":"G Porcelli","year":"2025","unstructured":"Porcelli G, D\u2019Accardo C, Angeloro F, Cucchiara M, Bianca P, Pantina VD, et al. Decoding cancer dormancy: integrative genomic, phenotypic and live-cell imaging analysis to reveal the hidden cancer cell reservoir. Mol Cancer. 2025;24:286.","journal-title":"Mol Cancer"},{"key":"3282_CR8","doi-asserted-by":"crossref","unstructured":"Duong HQ, Kafer G, Maugham-Macan M. Bone metastasis in endocrine-related cancer: unravelling invasion and destruction. Endocr Relat Cancer. 2025;32:e240294.","DOI":"10.1530\/ERC-24-0294"},{"key":"3282_CR9","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1158\/2159-8290.CD-23-1161","volume":"14","author":"D Rosano","year":"2024","unstructured":"Rosano D, Sofyali E, Dhiman H, Ghirardi C, Ivanoiu D, Heide T, et al. Long-term multimodal recording reveals epigenetic adaptation routes in dormant breast cancer cells. Cancer Discov. 2024;14:866\u201389.","journal-title":"Cancer Discov"},{"key":"3282_CR10","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1515\/jtim-2024-0022","volume":"12","author":"X Shao","year":"2024","unstructured":"Shao X, Xie N, Chen Z, Wang X, Cao W, Zheng Y, et al. Inetetamab for injection in combination with vinorelbine weekly or every three weeks in HER2-positive metastatic breast cancer: A multicenter, randomized, phase II clinical trial. J Transl Int Med. 2024;12:466\u201377.","journal-title":"J Transl Int Med"},{"key":"3282_CR11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11914-025-00934-1","volume":"23","author":"CJ Harris","year":"2025","unstructured":"Harris CJ, Stewart GR, Foston A, Green AC. Cancer cell dormancy in the bone microenvironment. Curr Osteoporos Rep. 2025;23:46.","journal-title":"Curr Osteoporos Rep"},{"key":"3282_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41568-025-00879-8","volume":"26","author":"C Mao","year":"2026","unstructured":"Mao C, Jiang D, Koong AC, Gan B. Exploiting metabolic cell death for cancer therapy. Nat Rev Cancer. 2026;26:27\u201345.","journal-title":"Nat Rev Cancer"},{"key":"3282_CR13","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13046-025-03430-7","volume":"44","author":"W Zou","year":"2025","unstructured":"Zou W, Han Z, Wang Z, Liu Q. Targeting glutamine metabolism as a potential target for cancer treatment. J Exp Clin Cancer Res. 2025;44:180.","journal-title":"J Exp Clin Cancer Res"},{"key":"3282_CR14","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1515\/jtim-2025-0059","volume":"13","author":"W Song","year":"2025","unstructured":"Song W, Zhang Y, Xu T, Fan T, Li J, Liu M, et al. Metabolic reprogramming in neurodegenerative diseases: new insights into mTOR-mediated microglial polarization. J Transl Int Med. 2025;13:610\u20133.","journal-title":"J Transl Int Med"},{"key":"3282_CR15","doi-asserted-by":"crossref","unstructured":"Xu L, Yin Y, Li Y, Chen X, Chang Y, Zhang H, et al. A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer. Proc Natl Acad Sci USA. 2021;118:e2012748118.","DOI":"10.1073\/pnas.2012748118"},{"key":"3282_CR16","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1038\/s41388-021-02155-z","volume":"41","author":"L Xu","year":"2022","unstructured":"Xu L, Zhao B, Butler W, Xu H, Song N, Chen X, et al. Targeting glutamine metabolism network for the treatment of therapy-resistant prostate cancer. Oncogene. 2022;41:1140\u201354.","journal-title":"Oncogene"},{"key":"3282_CR17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.4103\/aja20243","volume":"26","author":"J Wang","year":"2024","unstructured":"Wang J, Ding HK, Xu HJ, Hu DK, Hankey W, Chen L, et al. Single-cell analysis revealing the metabolic landscape of prostate cancer. Asian J Androl. 2024;26:451\u201363.","journal-title":"Asian J Androl"},{"key":"3282_CR18","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/pros.20677","volume":"68","author":"JM D\u2019Antonio","year":"2008","unstructured":"D\u2019Antonio JM, Ma C, Monzon FA, Pflug BR. Longitudinal analysis of androgen deprivation of prostate cancer cells identifies pathways to androgen independence. Prostate. 2008;68:698\u2013714.","journal-title":"Prostate"},{"key":"3282_CR19","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s43018-022-00431-9","volume":"3","author":"S Deng","year":"2022","unstructured":"Deng S, Wang C, Wang Y, Xu Y, Li X, Johnson NA, et al. Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance. Nat Cancer. 2022;3:1071\u201387.","journal-title":"Nat Cancer"},{"key":"3282_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.eururo.2013.08.011","volume":"66","author":"P Rajan","year":"2014","unstructured":"Rajan P, Sudbery IM, Villasevil ME, Mui E, Fleming J, Davis M, et al. Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy. Eur Urol. 2014;66:32\u20139.","journal-title":"Eur Urol"},{"key":"3282_CR21","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1111\/cas.16267","volume":"115","author":"S Pan","year":"2024","unstructured":"Pan S, Yin R, Zhu H, Shen S, Li Z, Liu B. Prostate cancer cancer-associated fibroblasts with stable markers post-androgen deprivation therapy associated with tumor progression and castration resistant prostate cancer. Cancer Sci. 2024;115:2893\u2013907.","journal-title":"Cancer Sci"},{"key":"3282_CR22","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1158\/0008-5472.CAN-13-2699","volume":"74","author":"Q Long","year":"2014","unstructured":"Long Q, Xu J, Osunkoya AO, Sannigrahi S, Johnson BA, Zhou W, et al. Global transcriptome analysis of formalin-fixed prostate cancer specimens identifies biomarkers of disease recurrence. Cancer Res. 2014;74:3228\u201337.","journal-title":"Cancer Res"},{"key":"3282_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/annonc\/mdx637","volume":"29","author":"S Jain","year":"2018","unstructured":"Jain S, Lyons CA, Walker SM, McQuaid S, Hynes SO, Mitchell DM, et al. Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy. Ann Oncol. 2018;29:215\u201322.","journal-title":"Ann Oncol"},{"key":"3282_CR24","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.stem.2024.05.008","volume":"31","author":"JS Kirk","year":"2024","unstructured":"Kirk JS, Wang J, Long M, Rosario S, Tracz A, Ji Y, et al. Integrated single-cell analysis defines the epigenetic basis of castration-resistant prostate luminal cells. Cell Stem Cell. 2024;31:1203\u201321.e7.","journal-title":"Cell Stem Cell"},{"key":"3282_CR25","doi-asserted-by":"crossref","unstructured":"Kisiel F, Ferguson D, Hart C, Brown M, Oliveira P, Sachdeva A, et al. Prognostic significance of PTEN loss in prostate cancer: a meta-analysis of Gleason grade and clinical outcomes. Cancers (Basel). 2025;17:2862.","DOI":"10.3390\/cancers17172862"},{"key":"3282_CR26","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41585-023-00726-1","volume":"20","author":"L Germain","year":"2023","unstructured":"Germain L, Lafront C, Paquette V, Neveu B, Paquette JS, Pouliot F, et al. Preclinical models of prostate cancer\u2014modelling androgen dependency and castration resistance in vitro, ex vivo and in vivo. Nat Rev Urol. 2023;20:480\u201393.","journal-title":"Nat Rev Urol"},{"key":"3282_CR27","doi-asserted-by":"publisher","first-page":"9605","DOI":"10.7150\/thno.63763","volume":"11","author":"T La","year":"2021","unstructured":"La T, Chen S, Guo T, Zhao XH, Teng L, Li D, et al. Visualization of endogenous p27 and Ki67 reveals the importance of a c-Myc-driven metabolic switch in promoting survival of quiescent cancer cells. Theranostics. 2021;11:9605\u201322.","journal-title":"Theranostics"},{"key":"3282_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-025-02344-3","volume":"23","author":"U Kahya","year":"2025","unstructured":"Kahya U, Lukiyanchuk V, Gorodetska I, Weigel MM, K\u00f6seer AS, Alkan B, et al. Disruption of glutamine transport uncouples the NUPR1 stress-adaptation program and induces prostate cancer radiosensitivity. Cell Commun Signal. 2025;23:351.","journal-title":"Cell Commun Signal"},{"key":"3282_CR29","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1158\/1078-0432.CCR-11-1867","volume":"18","author":"V Tzelepi","year":"2012","unstructured":"Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, et al. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res. 2012;18:666\u201377.","journal-title":"Clin Cancer Res"},{"key":"3282_CR30","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","volume":"1","author":"H Beltran","year":"2011","unstructured":"Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1:487\u201395.","journal-title":"Cancer Discov"},{"key":"3282_CR31","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.cell.2018.06.039","volume":"174","author":"DA Quigley","year":"2018","unstructured":"Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, et al. Genomic hallmarks and structural variation in metastatic prostate cancer. Cell. 2018;174:758\u201369.e9.","journal-title":"Cell"},{"key":"3282_CR32","doi-asserted-by":"publisher","first-page":"e1008540","DOI":"10.1371\/journal.pgen.1008540","volume":"17","author":"H Weber","year":"2021","unstructured":"Weber H, Ruoff R, Garabedian MJ. MED19 alters AR occupancy and gene expression in prostate cancer cells, driving MAOA expression and growth under low androgen. PLoS Genet. 2021;17:e1008540.","journal-title":"PLoS Genet"},{"key":"3282_CR33","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/ng.3419","volume":"47","author":"MM Pomerantz","year":"2015","unstructured":"Pomerantz MM, Li F, Takeda DY, Lenci R, Chonkar A, Chabot M, et al. The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat Genet. 2015;47:1346\u201351.","journal-title":"Nat Genet"},{"key":"3282_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2023.102248","volume":"47","author":"J Jiang","year":"2023","unstructured":"Jiang J, Hu Y, Fang D, Luo J. Glutamine synthetase and hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2023;47:102248.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"3282_CR35","doi-asserted-by":"crossref","unstructured":"Dai W, Shen J, Yan J, Bott AJ, Maimouni S, Daguplo HQ, et al. Glutamine synthetase limits \u03b2-catenin-mutated liver cancer growth by maintaining nitrogen homeostasis and suppressing mTORC1. J Clin Invest. 2022;132:e161408.","DOI":"10.1172\/JCI161408"},{"key":"3282_CR36","doi-asserted-by":"crossref","unstructured":"Kim GW, Lee DH, Jeon YH, Yoo J, Kim SY, Lee SW, et al. Glutamine synthetase as a therapeutic target for cancer treatment. Int J Mol Sci. 2021;22:1701.","DOI":"10.3390\/ijms22041701"},{"key":"3282_CR37","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/s41589-022-01154-9","volume":"19","author":"VH Villar","year":"2023","unstructured":"Villar VH, Allega MF, Deshmukh R, Ackermann T, Nakasone MA, Vande Voorde J, et al. Hepatic glutamine synthetase controls N(5)-methylglutamine in homeostasis and cancer. Nat Chem Biol. 2023;19:292\u2013300.","journal-title":"Nat Chem Biol"},{"key":"3282_CR38","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s43018-023-00649-1","volume":"5","author":"MV Recouvreux","year":"2024","unstructured":"Recouvreux MV, Grenier SF, Zhang Y, Esparza E, Lambies G, Galapate CM, et al. Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma. Nat Cancer. 2024;5:100\u201313.","journal-title":"Nat Cancer"},{"key":"3282_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1837998","volume":"16","author":"J Guo","year":"2026","unstructured":"Guo J, Wu K, Ma Z, Guo S, Wang F, Lu L. Androgen receptor reactivation in castration-resistant prostate cancer: mechanisms, epigenetic adaptation, and therapeutic vulnerabilities. Front Oncol. 2026;16:1837998.","journal-title":"Front Oncol"},{"key":"3282_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-03025-y","volume":"22","author":"W Chen","year":"2024","unstructured":"Chen W, Mao Y, Zhan Y, Li W, Wu J, Mao X, et al. Exosome-delivered NR2F1-AS1 and NR2F1 drive phenotypic transition from dormancy to proliferation in treatment-resistant prostate cancer via stabilizing hormonal receptors. J Nanobiotechnol. 2024;22:761.","journal-title":"J Nanobiotechnol"},{"key":"3282_CR41","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1158\/0008-5472.CAN-24-4809","volume":"86","author":"MM Nasr","year":"2026","unstructured":"Nasr MM, Wadie B, Li T, Frieling JS, du Bois H, Bishop RT, et al. PRDM16 regulates prostate cancer cell dormancy and prevents bone metastatic outgrowth. Cancer Res. 2026;86:604\u201321.","journal-title":"Cancer Res"},{"key":"3282_CR42","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41421-025-00817-w","volume":"11","author":"S Li","year":"2025","unstructured":"Li S, Zhang Y, Luo M, Zhou W, Chen Y, Wu D, et al. AR to GR switch modulates differential TDO2-Kyn-AhR signalling to promote the survival and recurrence of treatment-induced dormant cells in prostate cancer. Cell Discov. 2025;11:67.","journal-title":"Cell Discov"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03282-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03282-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03282-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:03:49Z","timestamp":1792541029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-026-03282-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3282"],"URL":"https:\/\/doi.org\/10.1038\/s41420-026-03282-w","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"5 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All procedures followed were in accordance with the ethical standards of the Ethical Committee of Anhui Medical University and with the Helsinki Declaration of 1964 and later versions. All human samples were obtained with the patients\u2019 written informed consent. All institutional and national guidelines for the care and use of laboratory animals were followed.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"420"}}